In the results of the SMR analysis, we discovered that HYKK (AGPHD1) was consistently identified in lung cancer data from both TRICL and ILCCO studies, and it was replicated specifically in non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma within the FinnGen dataset. Here, HYKK is linked to lung adenocarcinoma.